<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00913</drugbank-id>
  <drugbank-id>APRD00741</drugbank-id>
  <name>Anileridine</name>
  <description>Anileridine is a synthetic opioid and strong analgesic medication. It is a narcotic pain reliever used to treat moderate to severe pain. Narcotic analgesics act in the central nervous system (CNS) to relieve pain. Some of their side effects are also caused by actions in the CNS.</description>
  <cas-number>144-14-9</cas-number>
  <unii>71Q1A3O279</unii>
  <average-mass>352.4699</average-mass>
  <monoisotopic-mass>352.21507815</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>illicit</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Weijlard, J.and Pfister, K., Ill; US. Patent 2,966,490; December 27, 1960; assigned to Merck &amp; Co., Inc.</synthesis-reference>
  <indication>For treatment and management of pain (systemic) and for use as an anesthesia adjunct.</indication>
  <pharmacodynamics>Anileridine, a potent analgesic, is an analog of pethidine. Anileridine is useful for the relief of moderate to severe pain. It may also be used as an analgesic adjunct in general anesthesia in the same manner as meperidine to reduce the amount of anesthetic needed, to facilitate relaxation, and to reduce laryngospasm. In addition, anileridine exerts mild antihistaminic, spasmolytic and antitussive effects. Anileridine's main pharmacologic action is exerted on the CNS. Respiratory depression, when it occurs, is of shorter duration than that seen with morphine or meperidine when equipotent analgesic doses are used.</pharmacodynamics>
  <mechanism-of-action>Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Opioids such as anileridine close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.</mechanism-of-action>
  <toxicity>Symptoms of overexposure include dizziness, perspiration, a feeling of warmth, dry mouth, visual difficulty, itching, euphoria, restlessness, nervousness and excitement have been reported.</toxicity>
  <metabolism>Hepatic</metabolism>
  <absorption>Anileridine is absorbed by all routes of administration.</absorption>
  <half-life/>
  <protein-binding>&gt; 95%</protein-binding>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.</description>
    <direct-parent>Phenylpiperidines</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Piperidines</class>
    <subclass>Phenylpiperidines</subclass>
    <alternative-parent>Amino acids and derivatives</alternative-parent>
    <alternative-parent>Aniline and substituted anilines</alternative-parent>
    <alternative-parent>Aralkylamines</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Carboxylic acid esters</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Monocarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Phenethylamines</alternative-parent>
    <alternative-parent>Piperidinecarboxylic acids</alternative-parent>
    <alternative-parent>Primary amines</alternative-parent>
    <alternative-parent>Trialkylamines</alternative-parent>
    <substituent>Amine</substituent>
    <substituent>Amino acid or derivatives</substituent>
    <substituent>Aniline or substituted anilines</substituent>
    <substituent>Aralkylamine</substituent>
    <substituent>Aromatic heteromonocyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Carboxylic acid ester</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Monocarboxylic acid or derivatives</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Phenethylamine</substituent>
    <substituent>Phenylpiperidine</substituent>
    <substituent>Piperidinecarboxylic acid</substituent>
    <substituent>Primary amine</substituent>
    <substituent>Tertiary aliphatic amine</substituent>
    <substituent>Tertiary amine</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001408</drugbank-id>
      <name>Anileridine hydrochloride</name>
      <unii>915Q054DLC</unii>
      <cas-number>126-12-5</cas-number>
      <inchikey>ZYTHLJLPPSSDIP-UHFFFAOYSA-N</inchikey>
      <average-mass>425.39</average-mass>
      <monoisotopic-mass>424.1684336</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT001390</drugbank-id>
      <name>Anileridine phosphate</name>
      <unii>3584484N8V</unii>
      <cas-number>1976-75-6</cas-number>
      <inchikey>FLQCEKVTYABVSH-UHFFFAOYSA-N</inchikey>
      <average-mass>450.472</average-mass>
      <monoisotopic-mass>450.191973724</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">1-[2-(4-aminophenyl)ethyl]-4-phenyl-4-piperidinecarboxlic acid ethyl ester</synonym>
    <synonym language="spanish" coder="inn">Anileridina</synonym>
    <synonym language="english" coder="inn">Anileridine</synonym>
    <synonym language="latin" coder="inn">Anileridinum</synonym>
    <synonym language="english" coder="">ethyl 1-(2-(4-aminophenyl)ethyl)-4-phenyl-4-piperidinecarboxylate</synonym>
    <synonym language="english" coder="">ethyl 1-(4-aminophenethyl)-4-phenylisonipecotate</synonym>
    <synonym language="english" coder="">ethyl 1-(p-aminophenethyl)-4-phenylisonipecotate</synonym>
    <synonym language="english" coder="">N-(β-(p-aminophenyl)ethyl)-4-phenyl-4-carbethoxypiperidine</synonym>
    <synonym language="english" coder="">N-β-(p-aminophenyl)ethylnormeperidine</synonym>
  </synonyms>
  <products>
    <product>
      <name>Leritine Inj 25mg/ml</name>
      <labeller>Merck Frosst Canada &amp; Cie, Merck Frosst Canada &amp; Co.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00009857</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1966-12-31</started-marketing-on>
      <ended-marketing-on>2000-06-14</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Leritine Tablets 25mg</name>
      <labeller>Merck Frosst Canada &amp; Cie, Merck Frosst Canada &amp; Co.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00010014</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1966-12-31</started-marketing-on>
      <ended-marketing-on>2001-06-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Apodol</name>
      <company>Bristol-Myers Squibb</company>
    </international-brand>
    <international-brand>
      <name>Leritine</name>
      <company>Merck</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Leritine Tablets 25mg</name>
      <ingredients>Anileridine</ingredients>
    </mixture>
    <mixture>
      <name>Leritine Inj 25mg/ml</name>
      <ingredients>Anileridine</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers>
    <manufacturer generic="false" url="">Merck and co inc</manufacturer>
  </manufacturers>
  <prices/>
  <categories>
    <category>
      <category>Anesthetics</category>
      <mesh-id>D000777</mesh-id>
    </category>
    <category>
      <category>Anesthetics, General</category>
      <mesh-id>D018681</mesh-id>
    </category>
    <category>
      <category>Nervous System</category>
      <mesh-id>D009420</mesh-id>
    </category>
    <category>
      <category>Opioid Anesthetics</category>
      <mesh-id/>
    </category>
    <category>
      <category>Piperidines</category>
      <mesh-id>D010880</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="N01AH05">
      <level code="N01AH">Opioid anesthetics</level>
      <level code="N01A">ANESTHETICS, GENERAL</level>
      <level code="N01">ANESTHETICS</level>
      <level code="N">NERVOUS SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions>
    <food-interaction>Take without regard to meals.</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00829</drugbank-id>
      <name>Diazepam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Diazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00228</drugbank-id>
      <name>Enflurane</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Enflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00292</drugbank-id>
      <name>Etomidate</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Etomidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00474</drugbank-id>
      <name>Methohexital</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Methohexital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Clonidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00599</drugbank-id>
      <name>Thiopental</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Thiopental.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00633</drugbank-id>
      <name>Dexmedetomidine</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Dexmedetomidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00708</drugbank-id>
      <name>Sufentanil</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Sufentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00753</drugbank-id>
      <name>Isoflurane</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Isoflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00802</drugbank-id>
      <name>Alfentanil</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Alfentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00813</drugbank-id>
      <name>Fentanyl</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Fentanyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00818</drugbank-id>
      <name>Propofol</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Propofol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00899</drugbank-id>
      <name>Remifentanil</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Remifentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01028</drugbank-id>
      <name>Methoxyflurane</name>
      <description>The therapeutic efficacy of Methoxyflurane can be increased when used in combination with Anileridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01154</drugbank-id>
      <name>Thiamylal</name>
      <description>The therapeutic efficacy of Thiamylal can be increased when used in combination with Anileridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01159</drugbank-id>
      <name>Halothane</name>
      <description>The therapeutic efficacy of Halothane can be increased when used in combination with Anileridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01189</drugbank-id>
      <name>Desflurane</name>
      <description>The therapeutic efficacy of Desflurane can be increased when used in combination with Anileridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01221</drugbank-id>
      <name>Ketamine</name>
      <description>The therapeutic efficacy of Ketamine can be increased when used in combination with Anileridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>The therapeutic efficacy of Sevoflurane can be increased when used in combination with Anileridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01355</drugbank-id>
      <name>Hexobarbital</name>
      <description>The therapeutic efficacy of Hexobarbital can be increased when used in combination with Anileridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01440</drugbank-id>
      <name>gamma-Hydroxybutyric acid</name>
      <description>The therapeutic efficacy of gamma-Hydroxybutyric acid can be increased when used in combination with Anileridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04827</drugbank-id>
      <name>Urethane</name>
      <description>The therapeutic efficacy of Urethane can be increased when used in combination with Anileridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06690</drugbank-id>
      <name>Nitrous oxide</name>
      <description>The therapeutic efficacy of Nitrous oxide can be increased when used in combination with Anileridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06716</drugbank-id>
      <name>Fospropofol</name>
      <description>The therapeutic efficacy of Fospropofol can be increased when used in combination with Anileridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09072</drugbank-id>
      <name>Sodium oxybate</name>
      <description>The therapeutic efficacy of Sodium oxybate can be increased when used in combination with Anileridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09085</drugbank-id>
      <name>Tetracaine</name>
      <description>The therapeutic efficacy of Tetracaine can be increased when used in combination with Anileridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11371</drugbank-id>
      <name>Alfaxalone</name>
      <description>The therapeutic efficacy of Alfaxalone can be increased when used in combination with Anileridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11387</drugbank-id>
      <name>Chloroform</name>
      <description>The therapeutic efficacy of Chloroform can be increased when used in combination with Anileridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11549</drugbank-id>
      <name>Tiletamine</name>
      <description>The therapeutic efficacy of Tiletamine can be increased when used in combination with Anileridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11823</drugbank-id>
      <name>Esketamine</name>
      <description>The therapeutic efficacy of Esketamine can be increased when used in combination with Anileridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13229</drugbank-id>
      <name>Enibomal</name>
      <description>The therapeutic efficacy of Enibomal can be increased when used in combination with Anileridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13234</drugbank-id>
      <name>Propanidid</name>
      <description>The therapeutic efficacy of Propanidid can be increased when used in combination with Anileridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13323</drugbank-id>
      <name>Trichloroethylene</name>
      <description>The therapeutic efficacy of Trichloroethylene can be increased when used in combination with Anileridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13453</drugbank-id>
      <name>Xenon</name>
      <description>The therapeutic efficacy of Xenon can be increased when used in combination with Anileridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13598</drugbank-id>
      <name>Diethyl ether</name>
      <description>The therapeutic efficacy of Diethyl ether can be increased when used in combination with Anileridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13605</drugbank-id>
      <name>Phenoperidine</name>
      <description>The therapeutic efficacy of Phenoperidine can be increased when used in combination with Anileridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13690</drugbank-id>
      <name>Vinyl ether</name>
      <description>The therapeutic efficacy of Vinyl ether can be increased when used in combination with Anileridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14009</drugbank-id>
      <name>Medical Cannabis</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Medical Cannabis.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00186</drugbank-id>
      <name>Lorazepam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Lorazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00231</drugbank-id>
      <name>Temazepam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Temazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00349</drugbank-id>
      <name>Clobazam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Clobazam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00404</drugbank-id>
      <name>Alprazolam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Alprazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00475</drugbank-id>
      <name>Chlordiazepoxide</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Chlordiazepoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00546</drugbank-id>
      <name>Adinazolam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Adinazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00628</drugbank-id>
      <name>Clorazepic acid</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Clorazepic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00683</drugbank-id>
      <name>Midazolam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Midazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00690</drugbank-id>
      <name>Flurazepam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Flurazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00801</drugbank-id>
      <name>Halazepam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Halazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00842</drugbank-id>
      <name>Oxazepam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Oxazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00897</drugbank-id>
      <name>Triazolam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Triazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01068</drugbank-id>
      <name>Clonazepam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Clonazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01215</drugbank-id>
      <name>Estazolam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Estazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01489</drugbank-id>
      <name>Camazepam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Camazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01511</drugbank-id>
      <name>Delorazepam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Delorazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01544</drugbank-id>
      <name>Flunitrazepam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Flunitrazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01545</drugbank-id>
      <name>Ethyl loflazepate</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Ethyl loflazepate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01553</drugbank-id>
      <name>Cloxazolam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Cloxazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01558</drugbank-id>
      <name>Bromazepam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Bromazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01559</drugbank-id>
      <name>Clotiazepam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Clotiazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01567</drugbank-id>
      <name>Fludiazepam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Fludiazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01587</drugbank-id>
      <name>Ketazolam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Ketazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01588</drugbank-id>
      <name>Prazepam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Prazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01589</drugbank-id>
      <name>Quazepam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Quazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01594</drugbank-id>
      <name>Cinolazepam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Cinolazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01595</drugbank-id>
      <name>Nitrazepam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Nitrazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08811</drugbank-id>
      <name>Tofisopam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Tofisopam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09017</drugbank-id>
      <name>Brotizolam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Brotizolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09166</drugbank-id>
      <name>Etizolam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Etizolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12537</drugbank-id>
      <name>Benzodiazepine</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Benzodiazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13335</drugbank-id>
      <name>Pinazepam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Pinazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13437</drugbank-id>
      <name>Medazepam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Medazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13643</drugbank-id>
      <name>Loprazolam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Loprazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13837</drugbank-id>
      <name>Doxefazepam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Doxefazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13872</drugbank-id>
      <name>Lormetazepam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Lormetazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14028</drugbank-id>
      <name>Nordazepam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Nordazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14672</drugbank-id>
      <name>Oxazepam acetate</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Oxazepam acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14715</drugbank-id>
      <name>Cinazepam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Cinazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14719</drugbank-id>
      <name>Bentazepam</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with Bentazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15197</drugbank-id>
      <name>RSV-604</name>
      <description>The therapeutic efficacy of Anileridine can be increased when used in combination with RSV-604.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>4.05</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.5</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.24e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.64</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>paricalcitol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>352.4699</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>352.21507815</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CCOC(=O)C1(CCN(CCC2=CC=C(N)C=C2)CC1)C1=CC=CC=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C22H28N2O2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C22H28N2O2/c1-2-26-21(25)22(19-6-4-3-5-7-19)13-16-24(17-14-22)15-12-18-8-10-20(23)11-9-18/h3-11H,2,12-17,23H2,1H3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>LKYQLAWMNBFNJT-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>55.56</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>106.55</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>40.98</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>8.88</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>275-277</value>
      <source>Weijlard, J.and Pfister, K., Ill; US. Patent 2,966,490; December 27, 1960; assigned to Merck &amp; Co., Inc.</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.7</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>11387</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>61203</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>8944</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46505199</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D02941</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>8600</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164768817</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001135</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Anileridine</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201347</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways>
    <pathway>
      <smpdb-id>SMP0000674</smpdb-id>
      <name>Anileridine Action Pathway</name>
      <category>drug_action</category>
      <drugs>
        <drug>
          <drugbank-id>DB00171</drugbank-id>
          <name>ATP</name>
        </drug>
        <drug>
          <drugbank-id>DB00368</drugbank-id>
          <name>Norepinephrine</name>
        </drug>
        <drug>
          <drugbank-id>DB00913</drugbank-id>
          <name>Anileridine</name>
        </drug>
        <drug>
          <drugbank-id>DB00988</drugbank-id>
          <name>Dopamine</name>
        </drug>
        <drug>
          <drugbank-id>DB01345</drugbank-id>
          <name>Potassium cation</name>
        </drug>
        <drug>
          <drugbank-id>DB01373</drugbank-id>
          <name>Calcium</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>P35372</uniprot-id>
        <uniprot-id>P17787</uniprot-id>
        <uniprot-id>P43681</uniprot-id>
        <uniprot-id>O00555</uniprot-id>
        <uniprot-id>Q02641</uniprot-id>
        <uniprot-id>Q9NY47</uniprot-id>
        <uniprot-id>Q9Y5Y9</uniprot-id>
        <uniprot-id>Q07699</uniprot-id>
        <uniprot-id>Q9NZV8</uniprot-id>
        <uniprot-id>Q9NS61</uniprot-id>
        <uniprot-id>P05023</uniprot-id>
        <uniprot-id>P50993</uniprot-id>
        <uniprot-id>P13637</uniprot-id>
        <uniprot-id>Q13733</uniprot-id>
        <uniprot-id>P05026</uniprot-id>
        <uniprot-id>P14415</uniprot-id>
        <uniprot-id>P54709</uniprot-id>
        <uniprot-id>B7ZKV8</uniprot-id>
        <uniprot-id>P54710</uniprot-id>
        <uniprot-id>P01189</uniprot-id>
        <uniprot-id>P01203</uniprot-id>
        <uniprot-id>P16519</uniprot-id>
        <uniprot-id>Q05586</uniprot-id>
        <uniprot-id>Q12879</uniprot-id>
        <uniprot-id>Q8TCU5</uniprot-id>
        <uniprot-id>P35348</uniprot-id>
        <uniprot-id>P08908</uniprot-id>
        <uniprot-id>P23975</uniprot-id>
        <uniprot-id>P31645</uniprot-id>
        <uniprot-id>Q01959</uniprot-id>
        <uniprot-id>P21728</uniprot-id>
      </enzymes>
    </pathway>
  </pathways>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000770</id>
      <name>Mu-type opioid receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P35372" source="Swiss-Prot">
        <name>Mu-type opioid receptor</name>
        <general-function>Voltage-gated calcium channel activity</general-function>
        <specific-function>Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta-gamma dimer activating downstream cellular effectors. The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extend to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15. They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B. Also couples to adenylate cyclase stimulatory G alpha proteins. The selective temporal coupling to G-proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4. Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization. Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G-protein thus terminating signal transduction. The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins. The activation of the ERK pathway occurs either in a G-protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist-specific receptor phosphorylation. Acts as a class A G-protein coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling. Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G-protein coupling. Endogenous ligands induce rapid desensitization, endocytosis and recycling whereas morphine induces only low desensitization and endocytosis. Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties. Involved in neurogenesis. Isoform 12 couples to GNAS and is proposed to be involved in excitatory effects. Isoform 16 and isoform 17 do not bind agonists but may act through oligomerization with binding-competent OPRM1 isoforms and reduce their ligand binding activity.</specific-function>
        <gene-name>OPRM1</gene-name>
        <locus>6q24-q25</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>69-93
107-131
143-165
186-207
231-255
284-307
315-338</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.29</theoretical-pi>
        <molecular-weight>44778.855</molecular-weight>
        <chromosome-location>6</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8156</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>OPRM1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L25119</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>452073</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>319</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>319</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P35372</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>OPRM_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>hMOP</synonym>
          <synonym>M-OR-1</synonym>
          <synonym>MOP</synonym>
          <synonym>MOR1</synonym>
          <synonym>Mu opiate receptor</synonym>
          <synonym>Mu opioid receptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001536|Mu-type opioid receptor
MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCGPNRTDLGGRDSLCP
PTGSPSMITAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALAT
STLPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDF
RTPRNAKIINVCNWILSSAIGLPVMFMATTKYRQGSIDCTLTFSHPTWYWENLLKICVFI
FAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVFIVCWTPIHI
YVIIKALVTIPETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENFKRCFREFCIPTSSNI
EQQNSTRIRQNTRDHPSTANTVDRTNHQLENLEAETAPLP</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021649|Mu-type opioid receptor (OPRM1)
ATGGACAGCAGCGCTGCCCCCACGAACGCCAGCAATTGCACTGATGCCTTGGCGTACTCA
AGTTGCTCCCCAGCACCCAGCCCCGGTTCCTGGGTCAACTTGTCCCACTTAGATGGCAAC
CTGTCCGACCCATGCGGTCCGAACCGCACCGACCTGGGCGGGAGAGACAGCCTGTGCCCT
CCGACCGGCAGTCCCTCCATGATCACGGCCATCACGATCATGGCCCTCTACTCCATCGTG
TGCGTGGTGGGGCTCTTCGGAAACTTCCTGGTCATGTATGTGATTGTCAGATACACCAAG
ATGAAGACTGCCACCAACATCTACATTTTCAACCTTGCTCTGGCAGATGCCTTAGCCACC
AGTACCCTGCCCTTCCAGAGTGTGAATTACCTAATGGGAACATGGCCATTTGGAACCATC
CTTTGCAAGATAGTGATCTCCATAGATTACTATAACATGTTCACCAGCATATTCACCCTC
TGCACCATGAGTGTTGATCGATACATTGCAGTCTGCCACCCTGTCAAGGCCTTAGATTTC
CGTACTCCCCGAAATGCCAAAATTATCAATGTCTGCAACTGGATCCTCTCTTCAGCCATT
GGTCTTCCTGTAATGTTCATGGCTACAACAAAATACAGGCAAGGTTCCATAGATTGTACA
CTAACATTCTCTCATCCAACCTGGTACTGGGAAAACCTGCTGAAGATCTGTGTTTTCATC
TTCGCCTTCATTATGCCAGTGCTCATCATTACCGTGTGCTATGGACTGATGATCTTGCGC
CTCAAGAGTGTCCGCATGCTCTCTGGCTCCAAAGAAAAGGACAGGAATCTTCGAAGGATC
ACCAGGATGGTGCTGGTGGTGGTGGCTGTGTTCATCGTCTGCTGGACTCCCATTCACATT
TACGTCATCATTAAAGCCTTGGTTACAATCCCAGAAACTACGTTCCAGACTGTTTCTTGG
CACTTCTGCATTGCTCTAGGTTACACAAACAGCTGCCTCAACCCAGTCCTTTATGCATTT
CTGGATGAAAACTTCAAACGATGCTTCAGAGAGTTCTGTATCCCAACCTCTTCCAACATT
GAGCAACAAAACTCCACTCGAATTCGTCAGAACACTAGAGACCACCCCTCCACGGCCAAT
ACAGTGGATAGAACTAATCATCAGCTAGAAAATCTGGAAGCAGAAACTGCTCCGTTGCCC
TAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>beta-endorphin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein alpha-subunit binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein beta-subunit binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>morphine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>neuropeptide binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-activating dopamine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral response to ethanol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to morphine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of adenylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cAMP-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of nitric oxide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of Wnt protein secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuropeptide signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>opioid receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cAMP-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of ERK1 and ERK2 cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of neurogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of nitric oxide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of N-methyl-D-aspartate selective glutamate receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>